Wyeth Drops MedImmune FluMist Partnership, Will Transfer Clinical Data
This article was originally published in The Pink Sheet Daily
Executive Summary
MedImmune will continue developing the flu vaccine without a partner. The company has signaled that Wyeth might pull out of the partnership as a result of lower than expected revenues for the product.
You may also be interested in...
MedImmune Halves FluMist Price To $23.50; Taps Henry Schein As Distributor
The company had indicated a price reduction was under consideration based on weak sales during FluMist's first year on the market. In addition to selling FluMist, Henry Schein will also help promote the product to primary care physicians.
MedImmune Halves FluMist Price To $23.50; Taps Henry Schein As Distributor
The company had indicated a price reduction was under consideration based on weak sales during FluMist's first year on the market. In addition to selling FluMist, Henry Schein will also help promote the product to primary care physicians.
MedImmune Takes Back FluMist: Physician Education, Not DTC, Will Be Near-Term Focus
MedImmune will add 55 commercial positions to help compensate for the loss of the Wyeth partnership. MedImmune will pay Wyeth $25 mil. plus future royalties and milestones under dissolution agreement.